Composition for preventing relapse of lung cancer, and method for detecting lung cancer at high risk of relapse

The MECA-79 biomarker and photoimmunotherapy effectively address the inconsistency in predicting lung cancer recurrence by providing a precise diagnostic tool and preventive treatment, enhancing recurrence prediction accuracy and reducing recurrence rates.

JP2024157619APending Publication Date: 2024-11-08KANSAI MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023072060
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current methods for predicting lung cancer recurrence after complete resection are inconsistent due to variations in morphological judgments, and there is no effective strategy to prevent recurrence, especially in early stages like IA, where 15% of cancers still recur.

Method used

A biomarker, MECA-79, is used to predict lung cancer recurrence through immunostaining and photoimmunotherapy, involving an anti-MECA-79 antibody and a water-soluble silicone phthalocyanine reagent, and a lung cancer recurrence prediction device that compares MECA-79 measurement values with reference values to determine recurrence likelihood.

Benefits of technology

The MECA-79 biomarker allows accurate prediction of lung cancer recurrence and provides a means to prevent recurrence through targeted treatment, reducing variability in diagnosis and improving patient outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024157619000005
    Figure 2024157619000005
  • Figure 2024157619000006
    Figure 2024157619000006
  • Figure 2024157619000007
    Figure 2024157619000007
Patent Text Reader

Abstract

To provide a biomarker for predicting relapse of lung cancer, and a composition for preventing relapse of lung cancer.SOLUTION: The present invention provides a composition for preventing relapse of lung cancer that includes an anti-MECA-79 antibody, and a detection method for a marker to predict relapse of lung cancer that includes detecting a MECA-79 positive lung cancer cell in a lung cancer tissue taken from a patient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Disclosed herein are compositions for preventing the recurrence of lung cancer, and methods for detecting lung cancer that is likely to recur. [Background technology]

[0002] The basic radical treatment for early-stage lung cancer is surgery, and the basic postoperative treatment for disease stages judged to be at high risk of recurrence (IB or higher) is cytotoxic chemotherapy and molecular targeted therapeutic agents (Non-Patent Document 1).

[0003] Currently, indicators for predicting recurrence after complete resection of lung cancer are based on morphological findings such as the morphology of lung cancer cells, the spread of cancer cells, and the state of destruction of surrounding tissues by cancer cells (Non-Patent Documents 2 to 4). [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] National Comprehensive Cancer Network. Non-small cell lung cancer (Version 1. 2022) [Non-Patent Document 2] Moreira AL et al. J Thorac Oncol 2020 [Non-Patent Document 3] Shimada Y et al. J Thorac Oncol 2012 [Non-Patent Document 4] Dai C et al. J Thorac Oncol 2017 [Non-Patent Document 5] Okami J et al. J Thorac Oncol 2019 Summary of the Invention [Problem to be solved by the invention]

[0005] Conventional diagnoses based on morphological characteristics are subject to variability in judgment between observers (Non-Patent Document 2). Even in the earliest stage (IA stage) lung cancer, 15% of cases recur after complete resection, but there is no treatment strategy that can accurately predict and prevent recurrence (Non-Patent Document 5).

[0006] An objective of the present invention is to provide a biomarker for predicting the recurrence of lung cancer. Another objective of the present invention is to provide a composition for preventing the recurrence of lung cancer. [Means for solving the problem]

[0007] The present invention includes the following embodiments. Section 1. A composition comprising an anti-MECA-79 antibody for preventing the recurrence of lung cancer. Section 2. Item 2. The composition according to item 1, wherein the lung cancer is adenocarcinoma. Section 3. The composition according to item 1 for use in photoimmunotherapy. Section 4. Item 13. A photoimmunotherapy kit comprising the composition according to item 1 and a water-soluble silicon phthalocyanine reagent. Section 5. A method for detecting a marker for predicting recurrence of lung cancer, comprising detecting MECA-79-positive lung cancer cells in lung cancer tissue collected from a patient. Section 6. Item 6. The detection method according to Item 5, wherein detection of MECA-79-positive lung cancer cells indicates that the lung cancer has a high possibility of recurrence. Section 7. The detection method described in item 5, wherein detection of MECA-79 is performed by immunostaining. Section 8. A method for using MECA-79 present in lung cancer cells as a marker for predicting recurrence of lung cancer. Section 9. A test reagent containing an anti-MECA-79 antibody for detecting MECA-79 present in lung cancer cells as a marker for predicting the recurrence of lung cancer. Section 10. MECA-79 is a marker for predicting recurrence of lung cancer. Section 11. A lung cancer recurrence prediction device comprising a processing unit, The processing unit includes: A measurement value of MECA-79 in lung cancer tissue collected from the subject is obtained, The obtained measurement value is compared with the reference value. If the acquired measurement value is higher than the reference value, a label indicating that the lung cancer is likely to recur is output, and / or if the acquired measurement value is lower than the reference value, and outputting a label indicating that the lung cancer is unlikely to recur to the Recurrence prediction device. Section 12. When you run it on your computer, obtaining a measurement of MECA-79 in lung cancer tissue obtained from the subject; comparing the obtained measurements with a reference value; If the acquired measurement value is higher than the reference value, a label indicating that the lung cancer is likely to recur is output, and / or if the acquired measurement value is lower than the reference value, outputting a label indicating that the lung cancer is unlikely to recur; A lung cancer recurrence prediction program that Effect of the Invention

[0008] It is possible to predict the recurrence of lung cancer and also to prevent the recurrence of lung cancer. [Brief description of the drawings]

[0009] [Figure 1] 1 shows the configuration of a recurrence prediction system 1000. [Diagram 2] 1 shows the configuration of a recurrence prediction device 10. [Diagram 3] 13 shows a flow of processes executed by a recurrence prediction program. [Figure 4] The presence of MECA-79+ cancer cells was associated with recurrence and poor RFS after lobectomy for pStage IA LUAD [Diagram 5] The results of photoimmunotherapy targeting MECA-79 are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] 1. Composition One embodiment of the present invention relates to a composition for preventing the recurrence of lung cancer, the composition comprising an anti-MECA-79 antibody. Lung cancer is an epithelial malignant tumor originating in the lung. Lung cancer may include adenocarcinoma, large cell carcinoma, small cell carcinoma, and squamous cell carcinoma. Lung cancer is preferably adenocarcinoma.

[0011] The stage of lung cancer is preferably IA, IB, IIA, IIB, IIIA, IIIB, or IIIC in the lung cancer staging classification (TNM classification, 8th edition).

[0012] Recurrence refers to the reappearance of cancer or the expansion of cancer tissue after the cancer has seemingly disappeared or shrunk due to surgical resection, anticancer drug therapy, radiation therapy, etc. Generally, recurrence may include recurrence in the primary organ and metastasis, and the composition of the present invention is preferably used to prevent recurrence in the primary organ. Prevention can include inhibiting the reappearance of cancerous tissue and the spread of cancerous tissue. MECA-79 refers to the carbohydrate antigen (-Galb1-4(HSO3-6)GlcNAcb1-3Galb1-3GlcNAc-).

[0013] The anti-MECA-79 antibody is not limited as long as it is capable of binding to at least a portion of MECA-79. The "antibody" may be any of a polyclonal antibody, a monoclonal antibody, and an antigen-binding fragment thereof (e.g., Fab, F(ab'), F(ab)2, etc.). The immunoglobulin class and subclass of the antibody are not particularly limited. The antibody may be one screened from an antibody library, or may be a chimeric antibody, scFv, etc. The antibody does not necessarily have to be purified, and may be an antiserum or ascites fluid containing the antibody, or an immunoglobulin fraction fractionated therefrom. The anti-MECA-79 antibody may be a commercially available antibody (including an antigen-binding fragment generated from a commercially available antibody).

[0014] An example of a commercially available anti-MECA-79 antibody is Peripheral Node Addressin Antibody (MECA-79) - Non-Recombinant Monoclonal (clone: ​​MECA-79, Novus Biologicals, Englewood, CO, USA).

[0015] The composition may contain a pharma- ceutically acceptable carrier or additive. As the carrier, for example, diluents such as water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, etc., pH adjusters such as sodium citrate, sodium acetate, sodium phosphate, etc., buffers such as dipotassium phosphate, trisodium phosphate, sodium hydrogen phosphate, sodium citrate, etc., stabilizers such as sodium pyrosulfite, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, thioglycolic acid, thiolactic acid, etc., and sugars such as mannitol, inositol, maltose, sucrose, lactose, etc., can be used as molding agents for freeze-drying. The composition is provided as a dry product that does not include the diluent, and the diluent is removed at the time of use. may be added.

[0016] The dose of anti-MECA-79 antibody for preventing recurrence of lung cancer is not particularly limited as long as the effect of preventing recurrence of lung cancer is exhibited. In the case of local administration, the dose of anti-MECA-79 antibody is, for example, 1 cm of tissue. 2In the case of systemic administration, the dose of the anti-MECA-79 antibody is, for example, about 0.1 to 1,000 mg / kg, and preferably about 0.5 to 500 mg / kg per day for an adult (15 years of age or older) (calculated based on a body weight of about 60 kg). Preferably, the composition is used for photoimmunotherapy. Photoimmunotherapy is a method in which a complex in which an antibody is bound to a photosensitive substance is bound to target cells, and the target cells are then irradiated with light of a specific wavelength, thereby killing the target cells.

[0017] An example of the photosensitive material is IRdye700DX (IR700) dye, which is a water-soluble silicon phthalocyanine reagent. The wavelength of the light to be irradiated is from red to near infrared, for example, from 680 nm to 700 nm. The light irradiation is, for example, from 8 to 32 Joules / cm 2 in the range of 150 mW / cm 2 It can be done to some extent. The amount of anti-MECA-79 antibody used in photoimmunotherapy is approximately 1 cm of tissue. 2 The concentration is about 0.1 to 1,000 mg / kg, and preferably about 0.5 to 500 mg / kg.

[0018] 2. Photoimmunotherapy kit containing the composition Certain embodiments of the present invention relate to kits for photoimmunotherapy. The photoimmunotherapy kit may include the composition labeled with a photosensitizer described in 1 above, and a water-soluble silicon phthalocyanine reagent. The photoimmunotherapy kit may also include a package insert that describes how to use the composition and reagent, or that lists the URL of a web page that describes the method of use.

[0019] 3. Markers for predicting recurrence of lung cancer and methods for detecting same. An embodiment of the present invention relates to a lung cancer recurrence predictive marker consisting of MECA-79 and a method for detecting the lung cancer recurrence predictive marker (hereinafter, also referred to simply as a "detection method"). The detection method includes detecting MECA-79-positive lung cancer cells in lung cancer tissue collected from a patient. The definitions of lung cancer and MECA-79 are as described in 1 above. MECA-79 in lung cancer tissues can be detected by immunostaining.

[0020] When detecting MECA-79 by immunostaining, first, a biopsy tissue or resected tissue from a lung cancer portion taken from a patient is fixed with a known fixative such as formalin or paraformaldehyde, and then a paraffin-embedded block is prepared. Alternatively, the biopsy tissue or resected tissue is embedded in a resin for preparing frozen blocks, such as OCT Compound (registered trademark), with or without fixation, to prepare a frozen block. The prepared paraffin-embedded block or frozen block is sliced ​​to prepare tissue sections, which are then used for detection of MECA-79.

[0021] A known method can be used for immunostaining. For example, a thin section prepared from a paraffin-embedded block is subjected to deparaffinization and hydrophilization, followed by blocking and reacting with an anti-MECA-79 antibody. If necessary, antigen activation, endogenous peroxidase inactivation, or endogenous alkaline phosphatase inactivation may be performed before blocking. Antigen activation can be performed, for example, by immersing the section in a citrate buffer of about 95°C to 100°C and pH 5.8 to 9.0 for about 20 to 40 minutes. However, this treatment may be performed by other methods as long as the antigen can be activated. Inactivation of endogenous peroxidase is also known, and can be performed using methanol or the like with the addition of hydrogen peroxide. Inactivation of endogenous alkaline phosphatase is also known, and can be performed using alcohol to which hydrochloric acid has been added, or an aqueous solution of acetic acid.

[0022] In addition, sections prepared from frozen blocks are washed with water or a buffer to remove the embedding resin, and then blocked and reacted with an anti-MECA-79 antibody. Prior to blocking, antigen retrieval, endogenous peroxidase inactivation, or endogenous alkaline phosphatase inactivation may be performed according to the above-mentioned method. For immunostaining, the anti-MECA-79 antibody described above can be used.

[0023] Immunostaining may be a direct or indirect method. In the direct method, anti-MECA-79 antibody is directly labeled with a labeling substance such as peroxidase or alkaline phosphatase, and the anti-MECA-79 antibody bound to MECA-79 in the tissue on the slide glass is detected using the signals from these labeling substances as indicators. In the indirect method, unlabeled anti-MECA-79 antibody (primary antibody) is reacted with MECA-79 in the tissue on the slide glass, washed with buffer, etc., and then reacted with a secondary antibody that can bind to the primary antibody. The secondary antibody is labeled with a labeling substance such as peroxidase or alkaline phosphatase, and the anti-MECA-79 antibody bound to MECA-79 in the tissue on the slide glass is detected using the signals from these labeling substances as indicators.

[0024] When the labeling substance is peroxidase, for example, diaminobenzidine (DAB) is used as a substrate, and the color signal of the substrate is confirmed under an optical microscope to detect MECA-79 in the lung cancer tissue on the slide glass.

[0025] When the labeling substance is alkaline phosphatase, for example, New Fuchsin is used as a substrate, and MECA-79 in the tissue on the slide glass is detected by observing the color signal of the substrate under an optical microscope. After immunostaining, counterstaining is performed and the tissue is subjected to morphological observation.

[0026] In morphological observation, we will determine whether there is a MECA-79 signal in lung cancer cells. Because MECA-79 is present on the cell membrane, we will observe whether there is an immunostaining signal on the surface of lung cancer cells by morphological observation.

[0027] When a lung cancer cell has a signal by immunostaining, it can be determined that it is a "MECA-79 positive lung cancer cell." When a lung cancer cell has no signal by immunostaining, it can be determined that it is not a "MECA-79 positive lung cancer cell."

[0028] MECA-79 positive cancer cells in lung cancer cells may be detected by a flow cytometer. The cell sample to be subjected to the flow cytometer is prepared as follows. Lung cancer tissue collected from a patient is treated with a protease such as trypsin and ethylenediaminetetraacetate to prepare a cell suspension. The cell suspension is then mixed with an anti-MECA-79 antibody labeled with a fluorescent substance and each staining solution (propidium iodide, etc.) to prepare a cell sample.

[0029] In morphological observation or flow cytometry analysis, for example, when the positive rate of MECA-79 positive cells is equal to or higher than a reference value, it is suggested that the lung cancer is one with a high possibility of recurrence, whereas when the positive rate of MECA-79 positive cells is lower than the reference value, it is suggested that the lung cancer is one with a low possibility of recurrence.

[0030] The reference value can be determined by a receiver operating characteristic curve (ROC), discriminant analysis, mode method, Kittler method, 3σ method, p-tile method, etc. In addition, the sensitivity, specificity, negative predictive value, positive predictive value, first quartile, etc. can also be used as the reference value.

[0031] In addition, when the reference value is set to, for example, 1%, and the positive rate of MECA-79 positive cells in a lung cancer cell group is 1% or more, it is suggested that the lung cancer is a lung cancer with a high possibility of recurrence.In addition, when the positive rate of MECA-79 positive lung cancer cells in a lung cancer cell group is less than 1%, it is suggested that the lung cancer is a lung cancer with a low possibility of recurrence.

[0032] 4. Test reagents for detecting markers predicting recurrence of lung cancer One embodiment of the present invention relates to a test reagent for detecting the marker for predicting lung cancer recurrence, as described in 3 above. The test reagent is not limited as long as it contains an anti-MECA-79 antibody. The anti-MECA-79 antibody is as described in 1 above.

[0033] The antibody contained in the test reagent may be in a dry state or may be dissolved in a buffer such as phosphate-buffered saline. Furthermore, the test reagent may contain at least one of a stabilizer such as β-mercaptoethanol or DTT, a protector such as albumin, a surfactant such as polyoxyethylene (20) sorbitan monolaurate or polyoxyethylene (10) octylphenyl ether, or a preservative such as sodium azide. The antibody that binds to MECA-79 may be labeled with an enzyme or a fluorescent dye.

[0034] The test reagent for detecting MECA-79 may be provided as a test kit that includes the test reagent and a package insert that describes how to use the reagent or that includes a URL for a web page that describes how to use the reagent. In addition, when the antibody that binds to MECA-79 is an unlabeled primary antibody, the test kit may include a secondary antibody that is labeled with a labeling substance such as an enzyme. The labeling substance is as described in 3 above. In addition, the test kit may include a substrate that reacts with the enzyme.

[0035] 5. Lung cancer recurrence prediction device 5-1. Configuration of lung cancer recurrence prediction device One embodiment of the present disclosure relates to a lung cancer recurrence prediction system 1000 (hereinafter also simply referred to as "system 1000") and a lung cancer recurrence prediction device 10 (hereinafter also simply referred to as "device 10"). FIG. 1 is a schematic diagram of a system 1000, which in one embodiment may include an analysis device 5 in addition to the device 10. 2 shows a block diagram of the device 10. The device 10 may be connected to an input 111, an output 112 and a storage medium 113.

[0036] In the device 10, a processing unit 101, a main memory unit 102, a ROM (read only memory) 103, an auxiliary memory unit 104, a communication interface (I / F) 105, an input interface (I / F) 106, an output interface (I / F) 107, and a media interface (I / F) 108 are connected to each other via a bus 109 so as to be able to communicate data with each other. The main memory unit 102 and the auxiliary memory unit 104 may be collectively referred to simply as a memory unit. The memory unit stores the measurement values ​​and reference values ​​in a volatile or non-volatile manner.

[0037] The processing unit 101 is a CPU of the device 10. The processing unit 101 may be a GPU. The processing unit 101 executes a computer program stored in the auxiliary storage unit 104 or the ROM 103 and processes acquired data, thereby causing the device 10 to function.

[0038] The ROM 103 stores computer programs executed by the processing unit 101 and data used therein. The ROM 103 stores a boot program executed by the processing unit 101 when the device 10 is started up, and programs and settings related to the operation of the hardware of the device 10.

[0039] The main memory unit 102 is composed of a RAM (Random access memory). The main memory unit 102 is used to read out computer programs recorded in the ROM 103 and the auxiliary memory unit 104. The main memory unit 102 is also used as a working area when the processing unit 101 executes these computer programs.

[0040] The auxiliary storage unit 104 is composed of a hard disk, a semiconductor memory element such as a flash memory, an optical disk, etc. The auxiliary storage unit 104 stores various computer programs, such as an operating system and application programs, to be executed by the processing unit 101, and various setting data used for executing the computer programs. Specifically, reference values, etc. are stored in a non-volatile manner.

[0041] The communication I / F 105 is composed of a serial interface, a parallel interface, an analog interface consisting of a D / A converter, an A / D converter, etc., a network interface controller (NIC), etc. Under the control of the processing unit 101, the communication I / F 105 receives data from the analysis device 5 or other external devices, and the analysis device 5 transmits or displays information stored or generated by the device 10 to the outside as necessary. The communication I / F 105 may communicate with the analysis device 5 or other external devices via a network.

[0042] The input I / F 106 is composed of, for example, a serial interface, a parallel interface, and an analog interface including a D / A converter, an A / D converter, etc. The input I / F 106 accepts character input, clicks, voice input, etc. from the input unit 111. The accepted input contents are stored in the main memory unit 102 or the auxiliary memory unit 104.

[0043] The input unit 111 is composed of a touch panel, a keyboard, a mouse, a pen tablet, a microphone, etc., and inputs characters or voices to the device 10. The input unit 111 may be connected to the device 10 from outside, or may be integrated with the device 10.

[0044] The output I / F 107 is configured, for example, from an interface similar to the input I / F 106. The output I / F 107 outputs information generated by the processing unit 101 to the output unit 112. The output I / F 107 outputs information generated by the processing unit 101 and stored in the auxiliary storage unit 104 to the output unit 112.

[0045] The output unit 112 is composed of, for example, a display, a printer, etc., and displays the measurement results sent from the analysis device 5, various operation windows in the device 10, analysis results, etc.

[0046] The media I / F 108 reads, for example, application software etc. stored in the storage medium 113. The read application software etc. is stored in the main memory unit 102 or the auxiliary memory unit 104. The media I / F 108 also writes information generated by the processing unit 101 into the storage medium 113. The media I / F 108 writes information generated by the processing unit 101 and stored in the auxiliary memory unit 104 into the storage medium 113.

[0047] The storage medium 113 is composed of a USB memory flash, a hard disk, a CD-ROM, a DVD-ROM, etc. The storage medium 113 is connected to the media I / F 108 by a USB memory flash drive, a hard disk drive, a CD-ROM drive, a DVD-ROM drive, etc. The storage medium 113 may store application programs and the like for the computer to execute operations.

[0048] The processing unit 101 may obtain application software and various settings necessary for controlling the device 10 via a network instead of reading them from the ROM 103 or the auxiliary storage unit 104. It is also possible that the application program is stored in the auxiliary storage unit of a server computer on the network, and the device 10 accesses the server computer to download the computer program and store it in the ROM 103 or the auxiliary storage unit 104.

[0049] An operation system that provides a graphical user interface environment, such as Windows (registered trademark) manufactured and sold by Microsoft Corporation, is installed in the ROM 103 or the auxiliary storage unit 104. The application program according to the second embodiment runs on the operating system. That is, the device 10 may be a personal computer or the like.

[0050] The system 1000 does not need to be installed in one place, and the device 10 and the analysis device 5 may be located in different places and connected to each other via a network. The device 10 may be a device that does not require an operator by omitting the input unit 111 and the output unit 112. The analysis device 5 is, for example, a flow cytometer.

[0051] The analysis device 5 is connected to the device 10 by wire or wirelessly. The analysis device 5 A / D converts the measurement value of the MECA-79 positive cells and transmits it to the device 10 as digital data. The measurement value of the MECA-79 positive cells may be a positive rate. The measurement value of the MECA-79 positive cells may also be a count number of lung cancer cells or a number of MECA-79 positive cells.

[0052] 5-2. Processing of lung cancer recurrence prediction program An example of the process of the lung cancer recurrence prediction program is shown in Fig. 3. The device 10 executes the lung cancer recurrence prediction program to perform the following processes.

[0053] The processing unit 101 of the device 10 starts processing for predicting recurrence of lung cancer when an operator inputs a command to start processing from the input unit 111. In step S11, the processing unit 101 acquires, as a measurement value, the positivity rate of MECA-79 positive cancer cells in lung cancer tissue collected from a subject from the analysis device 5. Alternatively, the measurement value may be acquired by acquiring the count number of lung cancer cells and the MECA-79 positive cancer cells from the analysis device 5 and having the processing unit 101 calculate the positivity rate. Alternatively, the measurement value may be acquired by having the processing unit 101 accept an input of the positivity rate of MECA-79 positive cancer acquired by the operator through immunostaining of MECA-79.

[0054] Next, in step S12, the processing unit 101 compares the reference value of MECA-79 stored in the storage unit with the measurement value acquired in step S11. The reference value of MECA-79 is as described in 2. above.

[0055] If the acquired measurement value is higher than the reference value in step S13, the processing unit 101 proceeds to step S14 (YES), determines that the lung cancer has a high possibility of recurrence, and outputs a label indicating the determination result to the output unit 112 (step S16). If the acquired measurement value is lower than the reference value in step S13, the processing unit 101 proceeds to step S15 (NO), determines that the lung cancer has a low possibility of recurrence, and outputs a label indicating the determination result to the output unit 112 (step S16). If it is determined that the recurrence is highly likely, the label may include information indicating that "the recurrence is highly likely" or information indicating that "the recurrence is low". The information may be text data, or may be a mark such as an x, a circle, or an exclamation mark. EXAMPLES

[0056] The present invention will be described in more detail below by showing examples, but the present invention is not limited to these examples.

[0057] The following study was conducted in accordance with the principles of the Declaration of Helsinki, as revised in 2013. The study was also approved by the Kansai Medical University Hospital Research Ethics Committee (approval number: 2016662; approval date: September 12, 2016).

[0058] I. Materials and Methods 1. Patients to be studied We reviewed the records of 564 patients who underwent surgery for lung cancer at Kansai Medical University Hospital between January 1, 2009 and January 31, 2015. Inclusion criteria were patients with a pathological diagnosis of primary invasive nonmucinous adenocarcinoma (LUAD), pathological stage IA (according to the 8th edition of the TNM classification system), lobectomy or major resection, and tissue available for the study. Exclusion criteria were patients with adenocarcinoma in situ, minimally invasive adenocarcinoma, or invasive adenocarcinoma variants (invasive mucinous adenocarcinoma, colloid adenocarcinoma, fetal adenocarcinoma, intestinal adenocarcinoma, and adenocarcinoma not otherwise specified), surgery for biopsy / diagnosis, surgery for recurrent disease, or neoadjuvant therapy. Based on these criteria, 100 patients who underwent lobectomy with lobe-specific lymphadenectomy were included in the study.

[0059] 2. Diagnosis and immunohistochemical analysis of invasive non-mucinous adenocarcinoma Resected tissue samples were processed according to the General Rules for Clinical and Pathological Records of Lung Cancer of the Japan Lung Cancer Society. Pathological diagnosis of invasive nonmucinous adenocarcinoma was made according to the 2015 World Health Organization (WHO) histological classification of lung cancer. Grade determination was performed according to the International Association for the Study of Lung Cancer (IASLC) grading system for invasive adenocarcinoma based on a recent report. Vascular invasion, lymphatic intravascular spread, and Spread Through Air Spaces (STAS) were evaluated according to the literature: Am J Surg Pathol. 2015 Jun;39(6):793-801.

[0060] 3. Immunohistochemical analysis Formalin-fixed paraffin-embedded tissues cut into 5 μm-thick sections were used for immunohistochemical analysis. The following antibodies were used as primary antibodies for immunostaining: MECA-79 (PNAd; MECA-79, Novus Biologicals, Englewood, CO, USA; dilution factor 1:100) α-Smooth muscle actin (SMA; clone 1A4, Agilent Technologies, Santa Clara, CA; dilution 1:800) dendritic cell lysosomal associated membrane protein (DC-LAMP; Abcam, Cambridge, UK; dilution 1:75); B-cell lymphoma 6 (BCL-6; LN22, Nichirei Biosciences, Tokyo, Japan; dilution ratio 1:1).

[0061] PD-L1 expression was observed using a Dako Autostainer Link 48 system (Agilent Technologies, Santa Clara, CA) and a Dako 22C3 PharmDx and EnVision FLEX visualization system, as reported in the literature: Lung Cancer. 2018 Nov;125:230-237. PD-L1 expression in cancer cells was defined as "PD-L1 positive" when the expression level of PD-L1 in cancer cells was greater than 1% according to the literature. + The test determined that there were cancer cells.

[0062] The morphology of fibroblastic reticular cells (FRC) and cancer-associated fibroblasts (CAF) was determined according to a previous report (Transplantation. 2011 Jun 27;91(12):1398-405.), and α-smooth muscle actin positive fibroblastic reticular cells (α-SMA) were detected. + FRCs), and α-smooth muscle actin-positive cancer-associated fibroblasts (α-SMA + The presence or absence of MECA-79 positive high endothelial venules (MECA-79+ HEV-like vessels (regardless of morphology) and DC-LAMP + Mature dendritic cells were determined as previously described and were also classified as present or absent. + The presence or absence of tertiary lymphoid structures (TLS) in germinal centers was also evaluated. In addition, we evaluated whether MECA-79-positive lung cancer cells accounted for 1% or more of the total lung cancer cells. MECA-79 was detected mainly along the cell membrane as shown in Figure A. It was also detected in some parts of the cytoplasm.

[0063] 4.Statistical analysis Differences between nonparametric continuous and categorical variables were determined using Mann-Whitney U test and chi-square test, respectively. Univariate and multivariate logistic regression analyses were used to evaluate the diagnostic accuracy of pathological features in predicting postoperative recurrence of LUAD. Firth's penalization was used to treat subcomplete or complete separation (Reference: Stat Med. 2002 Aug 30;21(16):2409-19.). In the multivariate analysis, factors that were statistically significant in the univariate analysis (P < 0.10) were included, and pathological features that were significant in the multivariate logistic regression model (P < 0.05) were used to create variables for risk stratification.

[0064] Relapse-free survival (RFS) was calculated as the interval between the date of lung resection and the date of first documented recurrence or death from any cause. For censored patients, the date of last follow-up was used. RFS was analyzed visually using Kaplan-Meier estimated curves, and differences between groups were assessed using the log-rank test. Cox proportional hazards models were used for univariate and multivariate analysis of RFS. Multivariate analysis included baseline characteristics (age, sex, disease stage) and other factors that were significant (P < 0.10) in univariate analysis.

[0065] The software used for statistical analysis was GraphPad Prism version 6.07 (GraphPad Software, San Diego, LA, USA), JMP version 13.0.0 (SAS Institute, Cary, NC, USA), EZR version 1.54 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), and a modified version of R Commander version 4.2.0 (R Foundation for Statistical Computing, Vienna, Austria) for Windows (Microsoft, Redmond, WA). Statistical significance was set at P < 0.05. 5. Verification of the efficacy of photoimmunotherapy targeting MECA-79

[0066] PC-9 cells were plated in a 24-well plate at 5 × 10 4 Cells were seeded at 100 x 100 cells and cultured in RPMI medium (Wako Pure Chemical Industries, Ltd.) supplemented with 10% FBS (hereafter referred to as "culture medium"). Culture was performed overnight at 37°C. After washing the cells in the wells with additive-free medium (FBS-free, phenol red-free RPMI medium), IR700-labeled anti-MECA-79 antibody was added to a final concentration of 10 μg / mL and incubated at 37°C for 1 hour. After washing the inside of the wells with additive-free medium, the wells were irradiated with LED light (50 mW / cm 2 100 seconds: total dose 10 J / cm 2 The medium was replaced with fresh culture medium and incubated at 37°C for 24 hours. After incubation, cell viability was calculated using Cell Counting Kit-8 (Dojindo) according to the protocol provided by the manufacturer.

[0067] II. Results 1. Clinical characteristics of the patients studied The clinical and pathological characteristics of the study population according to recurrence status are summarized in Table 1. The median follow-up time of the patients was 7.5 years [range: 0.8-13.6 years]. Of the 100 patients included in the analysis, 10 (10%) experienced postoperative recurrence. Locoregional recurrence occurred in 90% (9 of 10), whereas distant metastases occurred in only 10% (1 of 10). The lung was the most common anatomical site of recurrence, accounting for 50% (5 of 10) of recurrent cases. As shown in Table 1, there were no significant differences in clinical or pathological characteristics between the patient group with and without recurrence.

[0068] [Table 1] *Pathological stage per the 8th edition of the TNM classification system. Values ​​for continuous variables are provided as median with range. CEA, carcinoembryonic antigen; IASLC, International Association for the Study of Lung Cancer; STAS, spread through air spaces; PD-L1, programmed cell death ligand-1; HEV, high endothelial venule; α-SMA, α-smooth muscle actin; TLS, tertiary lymphoid structure; BCL-6, B-cell lymphoma 6; DC-LAMP, dendritic cell lysosome-associated membrane protein.

[0069] 2. Relationship between pathological features and recurrence STAS, MECA-79 + Cancer cells, MECA-79 +The presence of HEV-like vessels and α-SMA+FRC was more frequently observed in patients with postoperative recurrence (P = 0.041, P < 0.001, P = 0.047, and P = 0.033, respectively). + None of the patients without CAF (n=26) experienced postoperative recurrence. As shown in Table 2, univariate logistic regression analysis with Firth's penalization showed that STAS, MECA-79, and ESRD were pathological factors predicting recurrence. + Cancer cells, α-SMA+CAFs, and MECA-79 + We identified the presence of HEV-like vessels. Among these candidate variables, MECA-79 + The presence of cancer cells was an independent predictor with an odds ratio of 12.4 (95% confidence interval, 1.91-109.6; P < 0.008), as determined by univariate logistic regression analysis with Firth's penalization. + The presence of cancer cells was further assessed using the Cox proportional hazards model.

[0070] [Table 2] IASLC, International Association for the Study of Lung Cancer; STAS, spread through air spaces; PD-L1, programmed cell death ligand-1; HEV, high endothelial venule; α-SMA, α-smooth muscle actin; CAF, cancer-associated fibroblast; FRC, fibroblastic reticular cell; TLS, tertiary lymphoid structure; BCL-6, B-cell lymphoma 6; GC, germinal center; DC-LAMP, dendritic cell lysosome-associated membrane protein; DC, dendritic cell.

[0071] 3. MECA-79 + Prognostic significance of the presence of cancer cells 5-year RFS is MECA-79 + MECA-79 was more effective than patients without cancer cells (91.2%) + Patients with cancer cells (44.4%) had a significantly worse outcome (P<0.001) (Figure A). + The presence of cancer cells was an independent risk factor for RFS, with a hazard ratio of 9.02 (95% confidence interval: 1.80-45.3, P<0.008) (Table 3).

[0072] [Table 3] *Pathological stage per the 8th edition of the TNM classification system.

[0073] 4. MECA-79 + Correlation between LUAD with cancer cells and radiological and other pathological features As shown in Table 4, the classification of nodules on high-resolution CT and the standardized maximum uptake values ​​were significantly higher in MECA-79 than in the control group. + There was no significant association with the presence or absence of cancer cells. + Patients with cancer cells tended to have solid nodules on high-resolution CT. + In LUAD containing cancer cells, vascular invasion, PD-L1 + Cancer cells, TLS with BCL-6 germinal centers, and α-SMA+FRC were observed more frequently (P=0.027, P=0.033, P=0.005, and P=0.002, respectively).

[0074] [Table 4] computed tomography; SUVmax, maximal standardized uptake value; 18-FDG-PET / CT, 18-fluorodeoxyglucose positron emission tomography / computed tomography; IASLC, International Association for the Study of Lung Cancer; STAS, spread through air spaces; PD-L1, programmed cell death ligand-1; HEV, high endothelial venule; α-SMA, α-smooth muscle actin; CAF, cancer-associated fibroblast; FRC, fibroblastic reticular cell; TLS, tertiary lymphoid structure; BCL-6, B-cell lymphoma 6; GC, germinal center; DC-LAMP, dendritic cell lysosome-associated membrane protein; DC, dendritic cell.

[0075] 4. MECA-79-targeted photoimmunotherapy Figure 5 shows the results of photoimmunotherapy targeting MECA-79. When light was irradiated, the cell viability was reduced in cells to which IR700-labeled anti-MECA-79 antibody was added (MECA-IR700 (+)) compared to cells to which IR700-labeled anti-MECA-79 antibody was not added (MECA-IR700 (-)). Furthermore, when light irradiation was not performed, no difference was observed between MECA-IR700 (+) and MECA-IR700 (-).

Claims

1. A composition comprising an anti-MECA-79 antibody for preventing the recurrence of lung cancer.

2. The composition of claim 1 , wherein the lung cancer is an adenocarcinoma.

3. The composition of claim 1 for use in photoimmunotherapy.

4. A photoimmunotherapy kit comprising the composition of claim 1 and a water-soluble silicon phthalocyanine reagent.

5. A method for detecting a marker for predicting recurrence of lung cancer, comprising detecting MECA-79-positive lung cancer cells in lung cancer tissue collected from a patient.

6. The method according to claim 5, wherein detection of MECA-79 positive lung cancer cells indicates that the lung cancer has a high possibility of recurrence.

7. The method according to claim 5, wherein the detection of MECA-79 is carried out by immunostaining.

8. A method for using MECA-79 present in lung cancer cells as a marker for predicting recurrence of lung cancer.

9. A test reagent containing an anti-MECA-79 antibody for detecting MECA-79 present in lung cancer cells as a marker for predicting the recurrence of lung cancer.

10. A marker for predicting recurrence of lung cancer consisting of MECA-79.

11. A lung cancer recurrence prediction device comprising a processing unit, The processing unit includes: Obtaining a measurement value of MECA-79 in lung cancer tissue collected from the subject; The obtained measurement value is compared with the reference value. If the acquired measurement value is higher than the reference value, a label indicating that the lung cancer is likely to recur is output, and / or if the acquired measurement value is lower than the reference value, and outputting a label indicating that the lung cancer is unlikely to recur to the Recurrence prediction device.

12. When you run it on your computer, Obtaining a measurement of MECA-79 in lung cancer tissue obtained from the subject; comparing the obtained measurements with a reference value; If the acquired measurement value is higher than the reference value, a label indicating that the lung cancer is likely to recur is output, and / or if the acquired measurement value is lower than the reference value, outputting a label indicating that the lung cancer is unlikely to recur; A lung cancer recurrence prediction program that

Citation Information

Patent Citations

  • Method for examining cancer and adenoma

    JP2009053204A

  • Anti-peripheral lymph node addressin antibodies and uses thereof

    JP2022520088A